Genenta Science S.p.A. (NASDAQ:GNTA - Get Free Report)'s stock price traded down 1.3% during trading on Friday . The company traded as low as $3.51 and last traded at $3.76. 22,483 shares changed hands during trading, an increase of 43% from the average session volume of 15,753 shares. The stock had previously closed at $3.81.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and set a $25.00 price objective on shares of Genenta Science in a research note on Wednesday, October 2nd.
Get Our Latest Research Report on Genenta Science
Genenta Science Stock Performance
The stock has a 50-day moving average of $4.88 and a 200-day moving average of $4.56.
Institutional Trading of Genenta Science
An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. acquired a new stake in Genenta Science S.p.A. (NASDAQ:GNTA - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 200,288 shares of the company's stock, valued at approximately $621,000. AlTi Global Inc. owned approximately 1.10% of Genenta Science at the end of the most recent reporting period. 15.13% of the stock is currently owned by institutional investors and hedge funds.
About Genenta Science
(
Get Free Report)
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
Further Reading
Before you consider Genenta Science, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genenta Science wasn't on the list.
While Genenta Science currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
